Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Skin diseases

FDA approves injectable psoriasis drug

The US Food and Drug Administration (FDA) has approved an injectable treatment, ixekizumab (Taltz; Eli Lilly), for adults with moderate to severe plaque psoriasis. 

The drug is a monoclonal antibody that inhibits interleukin-17A, which contributes to skin inflammation and the formation of plaques. The FDA advises that it is intended for patients who are candidates for systemic therapy, phototherapy or a combination of both. 

“[This] approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition,” explains Julie Beitz, director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. 

According to the FDA, ixekizumab’s safety and efficacy was established in three randomised, placebo-controlled clinical trials involving data from 3,866 participants with plaque psoriasis who were candidates for systemic or phototherapy therapy. The most common side effects include upper respiratory tract infections and injection site reactions.

In a review of the three trials, an improvement of 75% or greater was achieved in almost 90% of patients treated with ixekizumab, compared with rates of around 3–4% in those treated with placebo. In those receiving etanercept, a biologic used to treat psoriasis as well as conditions such as rheumatoid arthritis, 50% of patients improved. 

At the end of February 2016, the European Medicines Agency’s Committee for Medicinal Products for Human Use also recommended that a marketing authorisation be granted for ixekizumab. The recommendation will now go to the European Commission for approval. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200925

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Plaque psoriasis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.